How often esophageal cancer spreads to the left tracheobronchial (106TBL) lymph nodes
Official title: A Prospective Observational Study of Left Tracheobronchial Lymph Node Metastasis in Patients With Esophageal Cancer
Run by Fudan University · NCT07165210 · Data updated 2026-11-12
See how often and which factors are linked to spread to the left tracheobronchial (106TBL) lymph nodes in people with esophageal squamous cell carcinoma who are having curative esophagectomy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 85 Years |
| Sex | All |
| Enrollment | 1852 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | July 21, 2025 |
| Main results expected | July 21, 2027 |
| Study ends | July 21, 2030 |
| Registry record updated | September 10, 2025 |
| Trial ID | NCT07165210 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with esophageal squamous cell carcinoma staged cT1-4a N0/+ M0 who are medically fit for planned curative esophagectomy and have no history of other malignancy.
✕Probably not a fit
Patients with cervical (neck) esophageal cancer, metastatic disease, non-squamous histology, or who are unfit for surgery are unlikely to benefit from this observational protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational cohort at Fudan University Shanghai Cancer Center will document the incidence of metastasis to left tracheobronchial (106TBL) lymph nodes and identify clinicopathologic risk factors in patients with esophageal squamous cell carcinoma undergoing curative esophagectomy with lymph node dissection. Preoperative clinical staging (cT1-4a N0/+ M0) and surgical pathology will be used to determine 106TBL involvement, and perioperative outcomes and complications will be recorded. The work addresses limited sensitivity of current imaging for nodal spread and aims to clarify whether routine removal of 106TBL nodes is justified given potential airway and recurrent laryngeal nerve risks. Results will be compared with prior retrospective findings to inform the optimal scope of two-field lymph node dissection.
Why it matters
Potential benefit: If successful, the results could help surgeons avoid unnecessary removal of 106TBL nodes and reduce airway- and nerve-related complications while maintaining cancer control.
How similar studies have gone: Prior retrospective data from the investigators reported a low (~2%) 106TBL metastasis rate and no survival benefit from extended three-field dissection, so this prospective validation builds on limited earlier evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with esophageal squamous cell carcinoma * clinical staging: cT1-4a N0/+ M0. * no history of other malignancy. Exclusion Criteria: * esophageal cancer in the neck * poor physical status to have esophagectomy.
Where it's running
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Bin Li, MD
- Email: lb0256327@hotmail.com
- Phone: 086-021-64175590-82500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.